{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:52Z","timestamp":1761901312458,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.msard.2018.09.012","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:53:19Z","timestamp":1536778399000},"page":"74-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-2978","authenticated-orcid":false,"given":"Abigail E.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina I.","family":"Gout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed N.","family":"El-Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Neffendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.09.012_bib0001","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated, progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.09.012_bib0002","unstructured":"2 National Institute for Health and Clinical Excellence. Final Appraisal Determination, Natalizumab for the Treatment of Adults with Highly Active Relapsing\u2013Remitting Multiple Sclerosis. Issue date: June 2007."},{"key":"10.1016\/j.msard.2018.09.012_bib0003","first-page":"294","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015"},{"key":"10.1016\/j.msard.2018.09.012_bib0004","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2147\/OPTH.S113623","article-title":"Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the surveillance, epidemiology, and end results database (1973\u20132012)","volume":"10","author":"Mahendraraj","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.msard.2018.09.012_bib0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.012_bib0006","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMc0706103","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis","volume":"358","author":"Mullen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.09.012_bib0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJMc086089","article-title":"More on melanoma with transdifferentiation","volume":"359","author":"Panzara","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2018.09.012_bib0008","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.msard.2018.09.012_bib0009","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jamadermatol.2013.9411","article-title":"Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays","volume":"150","author":"Pharaon","year":"2014","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.msard.2018.09.012_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0033-1343793","article-title":"Natalizumab therapy for multiple sclerosis","volume":"33","author":"Derfuss","year":"2013","journal-title":"Semin. Neurol."},{"issue":"55","key":"10.1016\/j.msard.2018.09.012_bib0011","first-page":"414","article-title":"Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases","volume":"15","author":"Garofalo","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.msard.2018.09.012_bib0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90149-X","article-title":"Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation","volume":"77","author":"Qian","year":"1994","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.msard.2018.09.012_bib0013","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archdermatol.2010.243","article-title":"Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis","volume":"147","author":"Castela","year":"2011","journal-title":"Arch. Dermatol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:59Z","timestamp":1761900119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":13,"alternative-id":["S2211034818303249"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.012","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}